All News
Filter News
Found 809,010 articles
-
Rezolute Announces Change of Transfer Agent
12/28/2020
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder support provider. IssuerDirect will now be responsible for all transfers of Rezolute shares rather than VStock Transfer, LLC. Shareholders need take no action related to this transaction. About Rezolute, Inc. Rezol
-
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
12/28/2020
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date
-
McKesson Corporation Announces Third Quarter Fiscal 2021 Earnings Release Date and Participation in January Conferences
12/28/2020
McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2021 financial results before market open on Tuesday, February 2, 2021. The company will host a live webcast of the earnings conference call for investors at 8:00 AM Eastern Time to review its financial results. Additionally, McKesson management will be participating in the Goldman Sachs 13 th Annual Healthcare CEOs Unscripted Conference on Tuesday
-
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
12/28/2020
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in full their option to purchase additional shares of common stock at the public offering price, less underwr
-
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
12/28/2020
LORBRENA ® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA Supplemental New Drug Application being reviewed under FDA Real-Time Oncology Review (RTOR) and Project ORBIS pilot programs Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA
-
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
12/28/2020
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio – – First NDA submission by Ch
-
Capstone Therapeutics Announces Exercise of Secured Debt and Interest Conversion Option by BP Peptides, LLC and Change in Control
12/28/2020
Capstone Therapeutics (OTCQB:CAPS) EXERCISE OF SECURED DEBT AND INTEREST CONVERSION OPTION; ISSUANCE OF 24,900 SHARES OF THE COMPANYS COMMON STOCK On December 21, 2020, BP Peptides, LLC exercised its right to convert $572,700 of accrued interest and secured debt into 24,900 shares of the Companys Common Stock (exercise price of $23/share).
-
CB Scientific, Inc. (CBSC), Distributor Mango Wellness and My Cardia Thailand Well Positioned for Growth in 2021
12/28/2020
CB Scientific. Inc. (OTC:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT) in Thailan
-
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
12/28/2020
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
-
LYNPARZA® (olaparib) Receives Three New Approvals in Japan
12/28/2020
LYNPARZA ® (olaparib) Receives Three New Approvals in Japan Approvals in Three Types of Cancer Are Based on the PAOLA-1, PROfound and POLO Phase 3 Trials
-
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
12/28/2020
First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection
-
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesConference Call and Webcast Today at 4:30 p.m. ET
12/28/2020
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2020. Christopher U Missling, PhD, Pres
-
IMV Reports Update on COVID-19 Vaccine Program
12/28/2020
Preclinical safety, long duration of antibody titers and potential for protection demonstrated in preclinical immunogenicity and challenge studies Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months and ongoing Preclinical studies and revised clinical plan to account for evolving regulatory landscape and emergence of new variants
-
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
12/28/2020
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Al
-
Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy
12/28/2020
Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients u
-
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter
12/28/2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance S
-
emids Taps Industry Veteran Sriraman Nagarajan to Lead Life Sciences Business Unit
12/28/2020
emids, a leader in digital engineering and transformation solutions to the healthcare industry, today announced the appointment of Sriraman Nagarajan as President of its Life Sciences business unit.
-
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
12/28/2020
CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndicat
-
Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe
12/28/2020
Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced that it has entered into an exclusive agreement with Inceptua Group for the distribution and commercialization of Apealea® in Europe.
-
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
12/28/2020
The trial failed to meet its primary endpoint of complete remission (CR) rate CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance